First-In-Man Study for an Ophthalmic Synthetic Tissue Substitute

• ClinicalTrials.gov Identifier: NCT04037917
• Recruitment Status: Not yet recruiting
• First Posted: July 30, 2019
• Last Update Posted: July 10, 2020
• Sponsor: CorNeat Vision Ltd.
• Information provided by (Responsible Party): CorNeat Vision Ltd.

Study Description

Brief Summary:

Study Name: The CorNeat EverPatch - a First-In-Man Clinical Study for demonstrating the Safety of a Synthetic Tissue Substitute for concealment of artificial implants and glaucoma tube shunts

Objective: The objective of this clinical trial is to demonstrate the Safety of the Corneat Everpatch for concealment of artificial implants and glaucoma tube shunts

The study will consist 10 subjects requiring concealment of a glaucoma shunt or other ophthalmic implant. Eligible subjects who signs an ICF will be enrolled to the study. Subjects will be implanted with the Corneart EverPatch as part of a glaucoma shunt surgery or during a corrective surgery to repair a breached conjunctiva over an implanted device. Subjects will be monitored for a period of 12 months post-op during which follow up visits will occur at 1 week, 1, 2, 3, 6, 9 & 12 months following surgery including clinical examination of the operated eye using slit-lamp biomicroscopy and imaging using OCT or UBM (will be performed only at the 6 & 12 months follow up visits).

Condition or disease	Intervention/treatment	Phase
Glaucoma Eye; Tissue Breakdown	Device: CorNeat EverPatch	Not Applicable

Detailed Description:

Study Name: The CorNeat EverPatch - a First-In-Man Clinical Study for demonstrating the Safety of a Synthetic Tissue Substitute for concealment of artificial implants and glaucoma tube shunts

Objective: The objective of this clinical trial is to demonstrate the Safety of the Corneat Everpatch for concealment of artificial implants and glaucoma tube shunts

Study endpoints:

Primary Safety Endpoint:

The frequency of all Unanticipated Adverse Device-related Events (UADE) or treatment-related adverse events, during and following implantation and follow-up for up to 12 months will be 10% or less.

Effectiveness Endpoints:

Primary: Conjunctival integrity at the implantation site will be 90% or more. Secondary: Stability in patch dimensions, less than 10% change (length, projected width and thickness) measured by OCT after 1-week and follow-up for up to 12 months post-implantation in 90% of the implanted patients.

Intended uses: The CorNeat EverPatch intended use is concealment of artificial ophthalmic implants and glaucoma tube shunts.

The clinical investigation of the CorNeat EverPatch device is essential to validate its safety and efficacy in its target implantation site and to substantiate regulatory clearance. Clinical investigation of a medical device must be in compliance with Good Clinical Practice as set forth in ISO 14155, which addresses good clinical practices for the design, conduct, recording and reporting of clinical investigations carried out in human subjects for the purpose of assessing the safety and performance of medical devices for regulatory purposes, as well as applicable local laws and regulations.

Study Population: 10 subjects requiring concealment of artificial ophthalmic implants and glaucoma tube shunts. Unilateral and bi-lateral. The device can be implanted in patients' right or left eye (selection according to Principle Investigator's discretion).

Study Duration: Subjects will be followed-up for 12 months from device implantation date.

Visit Schedule:

• Screening: Day 0-7, Subjects will sign an Informed Consent Form (ICF) on screening visit and baseline assessments for clinical condition, concomitant medication and medical history data will be performed.

• Implantation: Implantation day will be recorded as day 0; enrollment day.

• Follow up visits at 1 week, 1, 2, 3, 6, 9 & 12-month post-op (total of 7 follow up visits).

At each follow up visit, subjects will be evaluated for: (i) conjunctival integrity; (ii) device dimensions, (iii) clinical evaluation; (iv) device retention and (v) any clinically necessary interim safety exam per PI decision. Additionally, at 6 & 12 months post-op, subjects will undergo an imaging evaluation of the device's dimensions (either by UBM or OCT).

Safety Assessment: A record of UADE as well as incidence and nature of Serious Adverse Events (SAE) will be recorded. Incidence and nature of Adverse Events (AE) will be collected throughout the study starting from implantation. The following types of events are outside of this category:

(i) Adverse events related to the disease such as glaucoma and not caused by implant concealment (ii) Adverse events related to the primary implant such as tube shunt blockage not related to implant concealment

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 10 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: The CorNeat EverPatch - a First-In-Man Clinical Study for Demonstrating the Safety of a Synthetic Tissue Substitute for Concealment of Artificial Implants and Glaucoma Tube Shunts
• Estimated Study Start Date: September 1, 2020
• Estimated Primary Completion Date: November 2021
• Estimated Study Completion Date: November 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: Synthetic Tissue Substitute; Corneat EverPatch - Synthetic Tissue Substitute for Covering Ophthalmic Implants	Device: CorNeat EverPatch; Covering Ophthalmic Implants

Outcome Measures

Primary Outcome Measures :

1. Number of treatment-related adverse events [ Time Frame: up to 12 months ]
   The frequency of all Unanticipated Adverse Device-related Events (UADE) or treatment-related adverse events

Secondary Outcome Measures :

1. Conjunctival integrity [ Time Frame: up to 12 months ]
   Conjunctival integrity at the implantation should be 90% or more as measured by Slit lamp examination
2. Stability in patch dimensions [ Time Frame: up to 12 months ]
   Stability in patch dimensions should show less than 10% change (length, projected width and thickness) measured by OCT after 1-week and follow-up for up to 12 months post-implantation in 90% of the implanted patients

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male or female
2. Aged ≥ 18 and ≤ 80 years on screening day
3. Concealment of an artificial ophthalmic implant or a glaucoma tube shunt is indicated.
4. Candidates must have the ability and willingness to attend all scheduled visits and comply with all study procedures
5. Adequate tear film and lid function
6. Visual acuity of light perception or better
7. Female patients of childbearing age must agree to use a method of contraception and have negative pregnancy test at screening. An effective method of contraception must be used throughout the study.

Exclusion Criteria:

1. Current retinal detachment
2. Active ocular or orbital infection
3. History or evidence of severe inflammatory eye diseases (i.e. uveitis, retinitis, scleritis) in one or both eyes within 6 months prior to planned implantation
4. History of ocular or periocular malignancy
5. History of extensive keloid formation
6. Any known intolerance or hypersensitivity to topical anesthetics, mydriatics, or component of the device
7. Signs of current infection, including fever and current treatment with antibiotics
8. Severe generalized disease that results in a life expectancy shorter than a year
9. Any clinical evidence that the investigator feels would place the subject at increased risk with the placement of the device
10. Currently pregnant or breastfeeding
11. Participation in any study involving an investigational drug or device within the past 30 days or 5 half-lives of the drug (whichever longer) or ongoing participation in a study with an investigational drug or device
12. Intraoperative complication that would preclude implantation of the study device.
13. Any traumatic perforation
14. Tissue gaps/weaknesses, resulting either from traumatic, disease-related or iatrogenic damage
15. Loss of scleral integrity where use of tissue or substitutes is indicated.

Contacts and Locations

Contacts

Contact: Gerry Tal; +972523562826; gerry@corneat.com

Contact: Ido Klein; +972549350507; ido@corneat.com

Locations

Canada, Ontario

Prism Eye Institute

Oakville, Ontario, Canada, L6H OJ8

Contact: Ayda Shahidi, OD PhD FAAO (905) 456-3937 ext 267 ayda.shahidi@prismeye.ca

Principal Investigator: Iqbal Ike K Ahmed, MD

Sub-Investigator: Devesh Varma, MD

Sub-Investigator: Diamond Tam, MD

Sub-Investigator: Matt Schlenker, MD

University Health Network - Toronto Western Hospital

Toronto, Ontario, Canada, M5T 2S8

Contact: Olivera Sutakovic, MD CCRC Olivera.Sutakovic@uhn.ca

Contact: Lina Chen, MD Lina.Chen@uhn.ca

Principal Investigator: David Rootman, MD, FRCS(C)

Sub-Investigator: Clara Chan, MD

Sponsors and Collaborators

CorNeat Vision Ltd.

More Information

• Responsible Party: CorNeat Vision Ltd.
• ClinicalTrials.gov Identifier: NCT04037917
• Other Study ID Numbers: SP-001
• First Posted: July 30, 2019
• Last Update Posted: July 10, 2020
• Last Verified: July 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Glaucoma; Ocular Hypertension; Eye Diseases